JARDIANCE® (Empagliflozin)
The content on this website is in relation to adult patients
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
1st clinically proven and licensed therapy across the LVEF spectrum1
Jardiance demonstrated superiority vs placebo for the CV Death/HHF composite in both HFrEF and HFpEF2,3
What's New
NICE Guidance
ESC heart failure guideline
Simple dosing for your patients with symptomatic chronic heart failure1
Jardiance demonstrated efficacy in the older patients that you often see and treat in clinical practice4
Safety Profile
ESC recommendations for pharmacological treatment of heart failure1,2
Class 1 recommendation: is recommended or indicated; evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Class 2b recommendation: may be considered; usefulness/efficacy is less well established by evidence/opinion. Level of evidence A: data derived from multiple randomised clinical trials or meta-analyses. Level of evidence B: data derived from a single randomised clinical trial or large non-randomised studies. Level of evidence C: consensus of opinion of the experts and/or small studies, retrospective studies, registries.
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; ARNI: angiotensin receptor-neprilysin inhibitor; CV: cardiovascular; ESC: European Society of Cardiology; HFA-ESC: Heart Failure Association of the ESC; HFmrEF: heart failure with mildly reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; SGLT2: sodium-glucose co-transporter-2.
- 1. McDonagh TA et al. Eur Heart J 2021;42:3599–3726
- 2. McDonagh TA et al. Eur Heart J 2023;44:3627–3639
- 3. Kemp CD and Conte JV. Cardiovasc Pathol 2012;21:365–371
- 4. Zhou Q et al. Front Cardiovasc Med 2021;8:678121
- 5. Redfield MM and Borlaug BA. JAMA 2023;14;329(10):827-838
Stay informed
Sign up to receive electronic communications from Boehringer Ingelheim, about BI's products, services and events.
Helpful resources supporting you every step of the way when you are treating your patients with JARDIANCE
Digital patient booklet
JARDIANCE Initiation & Management guide for T2D, CHF and CKD
Abbreviations
CI: confidence interval; CV: cardiovascular; CKD: chronic kidney failure; eGFR: estimated glomerular filtration rate; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; HHF: hospitalisation for heart failure; LVEF: left ventricular ejection fraction; NICE: National Institute for Health and Care Excellence.
References
- JARDIANCE® (empagliflozin) Summary of Product Characteristics (SmPC). Available at: http://www.medicines.org.uk/emc/medicine/28973.
- Packer M et al. N Engl J Med. 2020;383(15):1413–1424.
- Anker SD et al. N Engl J Med. 2021;385(16)1:1451–1461.
- Böhm M et al. J Am Coll Cardiol. 2022;80(1):1–18.
- National Institute for Health and Care Excellence (NICE) 2023. Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. Technology Appraisal Guidance TA929. Available from: https://www.nice.org.uk/guidance/ta929.
PC-GB-108857 V2
March 2024